FMC Corporation announced a strategic agreement with Corteva Agriscience that will expand FMC’s fluindapyr fungicide technology in the U.S. corn and soybean markets.
The collaboration between the two agricultural companies will enable more U.S. growers to combat challenging foliar diseases, such as tar spot and southern rust, with this novel fungicide active ingredient, a release stated.
Philadelphia-based FMC operates a research center in Newark and product lines that were acquired when Dow and DuPont agriscience operations were combined to form Corteva.
Under the terms of the agreement, both companies will market fluindapyr-based fungicide products to U.S. corn and soybean growers.
FMC will continue to offer Adastrio fungicide while developing new fungicide products containing fluindapyr. Corteva Agriscience will launch a fluindapyr-based product at the beginning of the 2026 growing season, pending Environmental Protection Agency registration.
"This strategic agreement will introduce FMC’s innovative fluindapyr technology into a broader segment of the U.S. corn and soybean markets, which represent roughly 95 million and 80 million planted acres, respectively," said Ronaldo Pereira, FMC president. "By partnering with Corteva, we're providing more growers with access to the advanced tools they need to effectively combat costly and challenging diseases, helping them protect yield potential and maximize their return on investment."
Fluindapyr, the active ingredient in Adastrio fungicide, provides extended residual control and effectively manages pathogens that have developed resistance to other fungicide classes.
"One of our goals is to make sure farmers have what they need to grow and harvest a successful crop,” said Jeremy Dirks, president, Corteva North America. "With the novel active ingredient, fluindapyr, we can provide growers with an additional effective disease management tool that complements the other fungicides in our portfolio.”
FMC has commercialized products containing fluindapyr in Argentina, Brazil, Colombia, Mexico, Paraguay, South Korea, and the United States. Pending regulatory decisions, FMC anticipates launching fluindapyr-based products in Chile, Honduras, India, and Ukraine.
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.